Gregory John, Feusner James
UMDNJ-New Jersey Medical School, Hackensack University Medical Center, Tomorrows Children's Institute, 30 Prospect Ave, Hackensack, NJ 07446, USA.
Best Pract Res Clin Haematol. 2003 Sep;16(3):483-94. doi: 10.1016/s1521-6926(03)00060-4.
Acute promyelocytic leukaemia (APL), designated M3, is a particularly interesting subtype of acute myeloid leukaemia (AML) that has unique molecular and clinical characteristics. It is characterized by an arrest of myeloid differentiation at the promyelocyte stage with abnormal proliferation of these cells. Recent paediatric and adult trials which included all-trans retinoic acid (ATRA) have shown that APL has significantly better survival rates than other subtypes of AML. While there is extensive literature on APL in adults, articles dedicated to describing solely paediatric patients are limited. This chapter focuses on the incidence, diagnosis, clinical characteristics, treatment, and survival rates of children with APL.
急性早幼粒细胞白血病（APL），分类为M3，是急性髓系白血病（AML）中一种特别有趣的亚型，具有独特的分子和临床特征。它的特点是在早幼粒细胞阶段髓系分化停滞，这些细胞异常增殖。最近包括全反式维甲酸（ATRA）的儿科和成人试验表明，APL的生存率明显高于AML的其他亚型。虽然关于成人APL的文献很多，但专门描述儿科患者的文章有限。本章重点关注儿童APL的发病率、诊断、临床特征、治疗和生存率。
